熱門資訊> 正文
加拉帕戈斯暂停入组GLPG 5301的1/2期研究
2024-08-03 03:05
- Galapagos (NASDAQ:GLPG) said it has paused enrollment in a Phase 1/2 study of its therapy candidate GLPG5301 after a case of Parkinsonism was observed.
- The Belgium-based biotech company said in its earnings release late Thursday that it has temporarily halted enrollment in the study, called PAPILIO-1, and submitted a protocol amendment to the European Medicines Agency.
- According to the National Institutes of Health, Parkinsonism is a “broad term referring to various neurodegenerative diseases that manifest with motor symptoms such as rigidity, tremors, and bradykinesia.”
- Galapagos (GLPG) has been evaluating GLPG5301, a CAR-T therapy, as a potential treatment for relapsed/refractory multiple myeloma, according to its website.
- The company added that it expects to resume recruitment for the study “in the coming months.”
More on Galapagos
- Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript
- Galapagos downgraded at Raymond James on lack of business development
- Galapagos, BridGene expand agreement to develop small molecule oncology asset
- Seeking Alpha’s Quant Rating on Galapagos
- Historical earnings data for Galapagos
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
